利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

186 条记录 (耗时 0.047 秒)

    Molecular in vitro diagnosis of breast cancer
    131.
    发明授权
    Molecular in vitro diagnosis of breast cancer 失效
    分子体外诊断乳腺癌

    公开(公告)号：US08299233B2

    公开(公告)日：2012-10-30

    申请号：US12811792

    申请日：2009-01-05

    申请人： Fabrice Andre ,  Stefan Michiels ,  Suzette Delaloge ,  Marc Spielmann ,  Philippe Dessen ,  Philippe Vielh

    发明人： Fabrice Andre ,  Stefan Michiels ,  Suzette Delaloge ,  Marc Spielmann ,  Philippe Dessen ,  Philippe Vielh

    IPC分类号： C07H21/04

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/156

    摘要： The invention relates to the use of a multiplicity of polynucleotide probe sets, the multiplicity of polynucleotide probe sets consisting in a combination of pools of polynucleotide probe sets, each polynucleotide probe set containing at least one polynucleotide probe chosen among a library of nucleic acid sequences, the polynucleotide probes involved in the combination of pools of polynucleotide probe sets of the multiplicity of polynucleotide probe sets being such that each polynucleotide probe specifically hybridizes with one gene, and/or at least one of its variants when present, for determining the variation of expression at least 12 genes, and their variants when present, in order to diagnose the benign or malignant state of a breast tumor.

    摘要翻译： 本发明涉及多种多核苷酸探针组的使用，多核苷酸探针组由多核苷酸探针组的组合组成，每个多核苷酸探针组含有选自核酸序列文库中的至少一种多核苷酸探针， 涉及多个多核苷酸探针组的多核苷酸探针组的组合的多核苷酸探针使得每个多核苷酸探针与一个基因和/或其存在的至少一个变体特异性杂交用于确定表达的变化 至少12个基因及其变异体，以便诊断乳腺肿瘤的良性或恶性状态。

    Method for screening peptides for use in immunotherapy
    135.
    发明授权
    Method for screening peptides for use in immunotherapy 有权
    筛选用于免疫治疗的肽的方法

    公开(公告)号：US07976843B2

    公开(公告)日：2011-07-12

    申请号：US12186856

    申请日：2008-08-06

    申请人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  David Alexandre Gross

    发明人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  David Alexandre Gross

    IPC分类号： A61K39/00 ,  C07K2/00

    CPC分类号： C07K14/005 ,  C07K14/71 ,  C12N9/1241 ,  C12N2740/16222 ,  G01N33/56977

    摘要： Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).

    摘要翻译： 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I）是新的。 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I），包括选择至少一种8-11个氨基酸（aa）的肽（II），潜在地代表I型呈递的表位， 来自提高细胞毒性T细胞（CTL）应答的蛋白质。 （II）对应于对I类分子具有低亲和力的非免疫原性肽。 制备（II）的变体（IIa），其中N末端aa被Tyr取代，并且通过鉴定对表达亲本蛋白的靶细胞产生CTL应答的那些检测其免疫原性。 然后鉴定衍生活性（IIa）的肽序列。 还包括以下独立权利要求：（1）以这种方式鉴定的衍生自（I）的免疫原性肽表位（IIa） 和（2）编码含有一个或多个，相同或不同的（IIa）拷贝的嵌合多肽（IV）的核酸（III）。

    Use of Inhibitors of Scinderin and/or Ephrin-A1 for Treating Tumors
    136.
    发明申请
    Use of Inhibitors of Scinderin and/or Ephrin-A1 for Treating Tumors 失效
    使用Scinderin和/或Ephrin-A1抑制剂治疗肿瘤

    公开(公告)号：US20090156531A1

    公开(公告)日：2009-06-18

    申请号：US12159460

    申请日：2006-12-28

    申请人： Salem Chouaib

    发明人： Salem Chouaib

    IPC分类号： A61K31/7105 ,  C12N5/06 ,  A61K31/711

    CPC分类号： C12N15/1135 ,  A61K31/7105 ,  A61K31/711 ,  C12N15/113 ,  C12N15/1136 ,  C12N2310/14

    摘要： The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene.

    摘要翻译： 本发明涉及使用scinderin和/或ephrin-A1抑制剂的表达或活性的抑制剂来增加肿瘤细胞对CTL杀伤的敏感性。 这样的抑制剂可以是例如靶向靶向ephrin-A1基因的scinderin基因和/或干扰RNA的干扰RNA。

    Method for screening peptides for use in immunotherapy
    137.
    发明授权
    Method for screening peptides for use in immunotherapy 有权
    筛选用于免疫治疗的肽的方法

    公开(公告)号：US07425606B2

    公开(公告)日：2008-09-16

    申请号：US10333430

    申请日：2001-07-20

    申请人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  Alexandre David Gross

    发明人： Kostas Kosmatopoulos ,  Sophie Tourdot ,  Antonio Scardino ,  Alexandre David Gross

    IPC分类号： C07K2/00

    CPC分类号： C07K14/005 ,  C07K14/71 ,  C12N9/1241 ,  C12N2740/16222 ,  G01N33/56977

    摘要： Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified. Independent claims are also included for the following: (1) immunogenic peptide epitopes (IIa) derived from (I) identified this way; and (2) nucleic acid (III) that encodes chimeric polypeptides (IV) containing one or more, same or different, copies of (IIa).

    摘要翻译： 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I）是新的。 鉴定由HLA（人白细胞抗原）I类分子呈递的亚显性/隐性表位（I），包括选择至少一种8-11个氨基酸（aa）的肽（II），潜在地代表I型呈递的表位， 来自提高细胞毒性T细胞（CTL）应答的蛋白质。 （II）对应于对I类分子具有低亲和力的非免疫原性肽。 制备（II）的变体（IIa），其中N末端aa被Tyr取代，并且通过鉴定对表达亲本蛋白的靶细胞产生CTL应答的那些检测其免疫原性。 然后鉴定衍生活性（IIa）的肽序列。 还包括以下独立权利要求：（1）以这种方式鉴定的衍生自（I）的免疫原性肽表位（IIa） 和（2）编码含有一个或多个，相同或不同的（IIa）拷贝的嵌合多肽（IV）的核酸（III）。

    Polypeptide Sequence Involved in the Modulation of the Immunosuppresive Effect of Viral Proteins
    139.
    发明申请
    Polypeptide Sequence Involved in the Modulation of the Immunosuppresive Effect of Viral Proteins 有权
    涉及病毒蛋白免疫抑制作用调节的多肽序列

    公开(公告)号：US20080008683A1

    公开(公告)日：2008-01-10

    申请号：US11547399

    申请日：2005-03-30

    申请人： Martial Renard ,  Marianne Mangeney ,  Thierry Heidmann

    发明人： Martial Renard ,  Marianne Mangeney ,  Thierry Heidmann

    IPC分类号： A61K38/00 ,  C07G1/00 ,  C07H21/04 ,  C07K16/00 ,  C12N15/00 ,  C12N5/04 ,  G01N33/53

    CPC分类号： C07K7/08 ,  C07K7/06

    摘要： The present invention relates to a polypeptide having a sequence of 7 to 20 amino acid residues, which is capable of modulating the immunosuppressive properties of a viral protein or a fragment thereof, against the host in which it is expressed (immunosuppression-modulatory sequence) when it substitutes the homologous sequence of the viral protein or fragment, the polypeptide including the minimum following consensus amino acid sequence: X1Y9Y10Y11CY12X2 wherein, X1 and X2 are selected to impact on the immunosuppressive properties, and Y9 to Y12 represent variable amino acid residues.

    摘要翻译： 本发明涉及具有7至20个氨基酸残基的序列的多肽，其能够调节其表达的宿主（免疫抑制调节序列）的病毒蛋白或其片段的免疫抑制性质（免疫抑制调节序列） 它代替病毒蛋白或片段的同源序列，所述多肽包括最小以下共有氨基酸序列：X 1 Y Y Y Y 其中，选择X 1和X 2，其中X 1，X 2，X 2，X 2， 以影响免疫抑制性质，Y 9至Y 12代表可变氨基酸残基。